@article{fc49e5f037ef4cc0ad505f1f47ed34bf,
title = "NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations",
abstract = "SIGNIFICANCE: The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high selectivity for ROS1 G2032R over TRK, and brain penetration mark the development of a distinct ROS1 TKI with the potential to surpass the limitations of earlier-generation TKIs for ROS1 fusion-positive patients. This article is highlighted in the In This Issue feature, p. 517.",
author = "Alexander Drilon and Horan, {Joshua C.} and Anupong Tangpeerachaikul and Benjamin Besse and Ou, {Sai Hong Ignatius} and Gadgeel, {Shirish M.} and Camidge, {D. Ross} and {van der Wekken}, {Anthonie J.} and Linh Nguyen-Phuong and Adam Acker and Clare Keddy and Nicholson, {Katelyn S.} and Satoshi Yoda and Scot Mente and Yuting Sun and Soglia, {John R.} and Kohl, {Nancy E.} and Porter, {James R.} and Shair, {Matthew D.} and Viola Zhu and Davare, {Monika A.} and Hata, {Aaron N.} and Pelish, {Henry E.} and Lin, {Jessica J.}",
note = "Publisher Copyright: {\textcopyright}2022 The Authors; Published by the American Association for Cancer Research.",
year = "2023",
month = mar,
day = "1",
doi = "10.1158/2159-8290.CD-22-0968",
language = "English (US)",
volume = "13",
pages = "598--615",
journal = "Cancer discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "3",
}